Compare iShares MSCI Germany (DAX) (EWG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Zoetis Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.22, while Zoetis Inc trades at $77.2 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares MSCI Germany (DAX) pays none, and iShares MSCI Germany (DAX) is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EWG | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $156.76 |
52-Week Low | $38.08 | $71.91 |
Market Cap | — | $31.25B |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.10, down 0.7% on the day, with a neutral technical signal and bearish moving averages. Key support is at $41 and resistance at $42. The stock lacks available financial ratios, and a dividend of $0.83 is scheduled for June 2026. Recent news highlights German economic policies and ECB rate decisions influencing European market sentiment.
The outlook is cautious due to limited fundamental data and mixed technical indicators. Risks include macroeconomic volatility from energy prices and ECB policy shifts. Analyst sentiment is neutral, with no clear consensus on price targets or ratings available.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
